KindlyMD (NASDAQ:NAKA) Shares Gap Down - Time to Sell?

Key Points

• KindlyMD's stock experienced a significant drop, opening at $1.22 after closing at $2.78, with the last trade recorded at $1.44 amid high volume of 67,293,162 shares.
• Despite the drop, Maxim Group has initiated coverage with a "buy" rating and a target price of $8.00, aligning with the average analyst rating for the stock.
• KindlyMD reported a negative EPS of ($0.34) last quarter, with a market cap of $466.39 million and significant negative net margins and returns on equity.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $2.78, but opened at $1.22. KindlyMD shares last traded at $1.44, with a volume of 67,293,162 shares.

Analysts Set New Price Targets

Separately, Maxim Group initiated coverage on KindlyMD in a research note on Wednesday, September 3rd. They set a "buy" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $8.00.

KindlyMD Stock Performance

The stock has a 50-day moving average of $8.04. The firm has a market capitalization of $529.38 million, a PE ratio of -1.63 and a beta of 33.96.

KindlyMD (NASDAQ:NAKA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share for the quarter. The business had revenue of $0.41 million for the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.